{"filing":{"accession_number":"0000950103-26-011979","cik":"0001860742","ticker":"BLCO","company_name":"Bausch \u0026 Lomb Corp","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-05","primary_document":"dp251415_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1860742/000095010326011979/dp251415_8k.htm"},"events":[{"id":25365,"run_id":23015,"accession_number":"0000950103-26-011979","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Bausch \u0026 Lomb appointed four new directors effective August 5, 2026: Thomas J. Appio (CEO of parent company Bausch Health), Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi, at the request of controlling shareholder Bausch Health Companies Inc. The appointments represent a significant governance change and board restructuring.","company_name":"Bausch \u0026 Lomb Corp","ticker":"BLCO","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26165,"accession_number":"0000950103-26-011979","item_number":"1.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 1.01 references incorporation by reference of information under Item 5.02 regarding the \"Ross Agreement,\" but the substantive disclosure in the press release (EX-99.1) focuses on board composition changes: appointment of four new directors (Thomas J. Appio, Robert Chersi, Laurence Paul, and Barbara Trebbi) and resignation of four departing directors (Steven Collis, Karen Ling, Thomas Ross, and Andrew von Eschenbach). While the filing cites Item 1.01 (Material Definitive Agreement), the actual content is a governance event involving director appointments and departures driven by majority shareholder Bausch Health's request. The \"Ross Agreement\" reference suggests a potential employment or severance arrangement with departing director Thomas Ross, but the primary disclosed action is the board restructuring itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:35:23.752095+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26166,"accession_number":"0000950103-26-011979","item_number":"5.02","item_title":"Departure of Directors or","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of four new directors (Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi) to Bausch + Lomb's board effective August 5, 2026, at the request of controlling shareholder Bausch Health Companies Inc. While the filing also mentions the simultaneous resignations of four directors, the principal disclosed action centers on the new appointments filling board vacancies. The appointments are material as they reflect a significant governance change driven by the controlling shareholder and include the CEO of the parent company (Appio) joining the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:35:23.752095+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26167,"accession_number":"0000950103-26-011979","item_number":"8.01","item_title":"Other Events","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material board composition change: four new directors (Thomas J. Appio, Robert Chersi, Laurence Paul, and Barbara Trebbi) were appointed effective August 5, 2026, replacing four departing directors (Steven Collis, Karen Ling, Thomas Ross, and Andrew von Eschenbach). This represents a significant governance event driven by Bausch Health's majority ownership position. While the press release also includes Q2 2026 financial results and reaffirmed guidance, the Item 8.01 disclosure centers on the board update announcement, making this a governance matter rather than an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:35:23.752095+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26165,"accession_number":"0000950103-26-011979","item_number":"1.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 1.01 references incorporation by reference of information under Item 5.02 regarding the \"Ross Agreement,\" but the substantive disclosure in the press release (EX-99.1) focuses on board composition changes: appointment of four new directors (Thomas J. Appio, Robert Chersi, Laurence Paul, and Barbara Trebbi) and resignation of four departing directors (Steven Collis, Karen Ling, Thomas Ross, and Andrew von Eschenbach). While the filing cites Item 1.01 (Material Definitive Agreement), the actual content is a governance event involving director appointments and departures driven by majority shareholder Bausch Health's request. The \"Ross Agreement\" reference suggests a potential employment or severance arrangement with departing director Thomas Ross, but the primary disclosed action is the board restructuring itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:35:23.752095+00:00","company_name":"Bausch \u0026 Lomb Corp","ticker":"BLCO","filing_date":"2026-08-06"},{"id":26166,"accession_number":"0000950103-26-011979","item_number":"5.02","item_title":"Departure of Directors or","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of four new directors (Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi) to Bausch + Lomb's board effective August 5, 2026, at the request of controlling shareholder Bausch Health Companies Inc. While the filing also mentions the simultaneous resignations of four directors, the principal disclosed action centers on the new appointments filling board vacancies. The appointments are material as they reflect a significant governance change driven by the controlling shareholder and include the CEO of the parent company (Appio) joining the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:35:23.752095+00:00","company_name":"Bausch \u0026 Lomb Corp","ticker":"BLCO","filing_date":"2026-08-06"},{"id":26167,"accession_number":"0000950103-26-011979","item_number":"8.01","item_title":"Other Events","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material board composition change: four new directors (Thomas J. Appio, Robert Chersi, Laurence Paul, and Barbara Trebbi) were appointed effective August 5, 2026, replacing four departing directors (Steven Collis, Karen Ling, Thomas Ross, and Andrew von Eschenbach). This represents a significant governance event driven by Bausch Health's majority ownership position. While the press release also includes Q2 2026 financial results and reaffirmed guidance, the Item 8.01 disclosure centers on the board update announcement, making this a governance matter rather than an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:35:23.752095+00:00","company_name":"Bausch \u0026 Lomb Corp","ticker":"BLCO","filing_date":"2026-08-06"}]}